Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

STLNSTLN
13 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in Starling Oncology, Inc.

CITADEL ADVISORS LLC holds 894,101 shares of STLN (Starling Oncology, Inc.), worth $4.9M as of 2026-Q2. The position was increased (+47.0% shares). STLN represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$4.9M

Current Shares

894,101

Total Value Change

+$4.5M

Total Shares Change

+854,540

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
894,101
+47.0%
$4.9M0.0%$5.43
37
2026-Q1
New
608,267
-
$1.9M0.0%$3.07
36
2025-Q4
Exited
0
-100.0%
$00.0%$3.56
0
2025-Q3
New
14,961
-
$52,2140.0%$3.49
32
2024-Q4
Exited
0
-100.0%
$00.0%$0.31
0
2024-Q3
Decreased
91,337
-66.1%
$29,8580.0%$0.33
0
2024-Q2
Increased
269,704
+794.7%
$124,0640.0%$0.46
24
2024-Q1
Decreased
30,146
-79.0%
$47,6310.0%$1.58
0
2023-Q4
Increased
143,840
+236.7%
$293,4340.0%$2.04
38
2023-Q3
New
42,717
-
$59,8040.0%$1.40
32
2022-Q2
Exited
0
-100.0%
$00.0%$5.06
0
2022-Q1
Increased
60,387
+52.6%
$431,0000.0%$7.13
33
2021-Q4
New
39,561
-
$386,0000.0%$9.75
33

Other major holders of STLN: FMR LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used